Sanofi + Regeneron will offer U.S. payers a further reduced net price for Praluent in alignment with a new value assessment for high-risk patients from the U.S. Institute for Clinical and Economic Review.

Sanofi and Regeneron have announced that to help ensure more affordable and timely access to patients most in need, the companies will offer U.S. payers that agree to reduce burdensome access barriers for high-risk patients a further reduced net price for Praluent (alirocumab) Injection in alignment with a new value assessment for high-risk patients from the U.S. Institute for Clinical and Economic Review (ICER). The companies will take a precision medicine approach, to address the burden of cardiovascular disease, focusing efforts on high-risk patients most vulnerable for future cardiovascular (CV) events, such as those who have suffered a previous coronary event and are unable to reduce their LDL cholesterol (LDL-C) below 100 mg/dL despite maximally-tolerated statin therapy.

In keeping with ICER's established "in confidence" procedures, Sanofi and Regeneron provided early access to data from the ODYSSEY OUTCOMES trial to ICER, an independent organization that evaluates the value of prescription drugs and other health care innovations, to enable a revised assessment of alirocumab value incorporating the ODYSSEY OUTCOMES results.

Sanofi and Regeneron will be meeting with U.S. health plans to discuss potential net pricing adjustments for those that agree to provide straightforward access for high-risk patients. The companies plan to work with cardiology healthcare professionals to define best practices in terms of reducing barriers to access in order to ensure that patients in need have their prescriptions filled quickly and efficiently. .